Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-small Cell Lung Cancer Metastatic × Immune Checkpoint Inhibitors × Clear all
NCT04836728 2025-03-13

CCICC-002b

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
156 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡